Navigation Links
It's Good News for The Lungs!

MIAMI, Jan. 28 /PRNewswire/ -- The Expand-A-Lung Breathing Resistance Exerciser has successfully accomplished the crossover from the sports respiratory fitness training market into the respiratory therapy market for COPD patients. Jorge Brouwer, President of Expand-A-Lung, Inc., and inventor of the most compact (4") breathing exerciser, originally marketed this product for athletes seeking a pocket size portable respiratory exerciser to increase lung capacity for endurance fitness training.

*(PHOTO 72dpi:

*(Photo Caption: Expand-A-Lung Breathing Resistance Exerciser.)

When asked about the 4 year marketing evolution of his product, Mr. Brouwer said, "It first caught on quickly among freedivers and triathletes, and then it trickled down into all the other endurance sports."

"In 2004 The Los Angeles Times did a review of respiratory fitness trainers, and the Expand-A-Lung was selected as the top choice for athletes. This is when our sales really took off! Little did we know that there was another huge market around the corner waiting to discover our product."

"In 2005 I gave a sample of our product to my uncle Bob, who suffers from shortness of breath due to Chronic Obstructive Pulmonary Disease (COPD). The very next day he called me to let me know that he wanted to invest all his savings into my business. I guess that meant that it worked very well for COPD symptoms!"

Brouwer started targeting this market through search engines' campaigns. Two years later by the end of 2007, 49.7% of Expand-A-Lung's total sales came from COPD patients looking to improve their shortness of breath symptoms "DRUG FREE."

The Expand-A-Lung is sold directly to the consumer through two separate web sites for $29.95 ea. For contact information call (305) 665-5787 or: For athletes, visit

For COPD patients, visit

This release was issued on behalf of the above organization by Send2Press(R), a unit of Neotrope(R).

SOURCE Expand-A-Lung, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Post Your Comments:
(Date:11/27/2015)... , November 27, 2015 ... Growing popularity of companion diagnostics is ... cancer biomarkers market with pharmaceutical companies and ... companion diagnostic tests. . ... Complete report on global cancer biomarkers ...
(Date:11/26/2015)... November 26, 2015 --> ... specializing in imaging technologies, announced today that it has received ... of the Horizon 2020 European Union Framework Programme for Research ... clinical trial in breast cancer. , --> ... --> --> The study aims ...
(Date:11/25/2015)... Nov. 25, 2015  PharmAthene, Inc. (NYSE MKT: PIP) ... a stockholder rights plan (Rights Plan) in an effort ... carryforwards (NOLs) under Section 382 of the Internal Revenue ... PharmAthene,s use of its NOLs could be substantially ... defined in Section 382 of the Code. In general, ...
(Date:11/25/2015)... , November 25, 2015 Studies ... and human plaque and pave the way for more effective ... in cats     --> ... commonly diagnosed health problems in cats, yet relatively little was ... Two collaborative studies have been conducted by researchers from the ...
Breaking Biology Technology:
(Date:11/12/2015)...  Arxspan has entered into an agreement with ... use of its ArxLab cloud-based suite of biological ... will support the institute,s efforts to electronically manage ... internally and with external collaborators. The ArxLab suite ... Institute,s electronic laboratory notebook, compound and assay registration, ...
(Date:11/10/2015)... Nov. 10, 2015 About ... that helps to identify and verify the identity ... considered as the secure and accurate method of ... a particular individual because each individual,s signature is ... especially when dynamic signature of an individual is ...
(Date:11/2/2015)... Nov. 2, 2015  SRI International has been awarded ... preclinical development services to the National Cancer Institute (NCI) ... provide scientific expertise, modern testing and support facilities, and ... pharmacology and toxicology studies to evaluate potential cancer prevention ... The PREVENT Cancer Drug Development Program is an NCI-supported ...
Breaking Biology News(10 mins):